FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APPROVAL
- 1	

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PARVEN ALVIN S					2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [ALXN]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
PARVEN ALVIN 5												X Directo	r	10% Ov	/ner	
(Last) (First) (Middle)					-							Officer below)	(give title	Other (s below)	pecify	
C/O ALEXION PHARMACEUTICALS INC					3. Date of Earliest Transaction (Month/Day/Year) 05/08/2012											
352 KNOTTER DRIVE					05/00/2012											
					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)		_										,	led by One Rep	orting Persor	,	
CHESHI	IRE C	Γ	06410										led by More tha	n One Repor	ting	
(City)	(9)	tate)	(Zip)	_								Person				
(City)	(5															
		Tal	ole I - Non-D	erivativ	/e Se	curities	Ac	quired, Dis	sposed o	f, or Ber	neficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				e	Execution D			Code (Insti				5. Amour Securitie Beneficia Owned F	s Form (D) of (I) (In	n: Direct Ind r Indirect Bei str. 4) Ow	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						((A) or		Τ	Reported					
								Code V	Amount	(D) Price		(Instr. 3 a				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
				1	, can	1						1	I	L	1	
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	4. Transa Code r) 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Option to Purchase Common Stock	\$85.75	05/08/2012		A		3,237 ⁽¹⁾		08/08/2012	05/08/2022	Common Stock, par value \$.0001 per share	3,237	\$0	3,237	D		

Explanation of Responses:

1. These options will vest in four quarterly installments during the one year period commencing on May 8, 2012 and ending on May 8, 2013.

/s/ Alvin Parven

05/09/2012

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.